ImmunityBio (IBRX) Total Current Liabilities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Total Current Liabilities data on file, last reported at $68.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $68.0 million, up 38.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $68.0 million (up 38.1% YoY), and the FY2025 annual result was $61.8 million, up 12.39% from the prior year.
• Total Current Liabilities climbed to $68.0 million in Q1 2026 per IBRX's latest filing, from $61.8 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $613.5 million in Q2 2023 and troughed at $49.2 million in Q1 2025.
• A 5-year average of $186.7 million and a median of $62.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Current Liabilities jumped 405.25% in 2022, then tumbled 90.48% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $500.9 million in 2022, then sank by 88.36% to $58.3 million in 2023, then decreased by 5.73% to $54.9 million in 2024, then climbed by 12.39% to $61.8 million in 2025, then grew by 10.04% to $68.0 million in 2026.
• Business Quant data shows IBRX's Total Current Liabilities at $68.0 million in Q1 2026, $61.8 million in Q4 2025, and $57.1 million in Q3 2025.